| Name | Title | Contact Details |
|---|
At Carolina Pines Regional Medical Center, we "care for our own, right here at home." A leader in providing quality health care services to the people of several counties in northeastern South Carolina, patients have come to rely on our experienced, skilled staff and physicians to provide them with the highest level of care and compassion. Through the facilities on our campus, including a 116-bed acute care hospital and an adjoining medical office building, we provide comprehensive services with two things in mind: the care and comfort of our patients. From routine checkups to complex, state of the art surgery, Carolina Pines Regional Medical Center wants to be your health care provider of choice. Our goal is to be valued for our leadership, expertise and the ability to positively impact the quality of life for the citizens in our service area which includes Darlington, Chesterfield, Lee and Marlboro Counties. It is our privilege to care for our own, right here at home. This hospital is partially owned by physicians.
Excedrin is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Nimble journey began with a loved one who was sick. I found myself visiting the pharmacy multiple times per week rather than caring for my family member. This inspired me to build a different approach – an experience that centered around the patient`s needs and the provider`s workflow. My goal was that customers would LOVE the experience so much that they would tell the world about it.
Through concierge medicine, SignatureMD creates doctor-patient partnerships that are based on extraordinary understanding and trust.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.